Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters

Therapeutic Methods and Therapies TCIM
Database
Language
Affiliation country
Publication year range
1.
Behav Brain Res ; 353: 11-20, 2018 11 01.
Article in English | MEDLINE | ID: mdl-29953903

ABSTRACT

Aberrant activation of toll-like receptor (TLR)s results in persistent and prolonged neuroinflammation and has been implicated in the pathogenesis and exacerbation of psychiatric and neurodegenerative disorders. TLR3 coordinates the innate immune response to viral infection and recent data have demonstrated that inhibiting fatty acid amide hydrolase (FAAH), the enzyme that primarily metabolizes anandamide, modulates TLR3-mediated neuroinflammation. However, the physiological and behavioural consequences of such modulation are unknown. The present study examined the effect of URB597, a selective FAAH inhibitor, on neuroinflammation, physiological and behavioural alterations following administration of the TLR3 agonist and viral mimetic poly I:C to female rats. URB597 attenuated TLR3-mediated fever, mechanical and cold allodynia, and anxiety-like behaviour in the elevated plus maze and open field arena. There was no effect of URB597 on TLR3-mediated decreases in body weight and no effect in the sucrose preference or forced swim tests. URB597 attenuated the TLR3-mediated increase in the expression of CD11b and CD68, markers of microglia/macrophage activation. In summary, these data demonstrate that enhancing FAAH substrate levels suppresses TLR3-mediated microglia/macrophage activation and associated changes in fever, nociceptive responding and anxiety-related behaviour. These data provide further support for FAAH as a novel therapeutic target for neuroinflammatory disorders.


Subject(s)
Amidohydrolases/antagonists & inhibitors , Anxiety/drug therapy , Fever/drug therapy , Hypothalamus/drug effects , Nociceptive Pain/drug therapy , Toll-Like Receptor 3/metabolism , Amidohydrolases/metabolism , Animals , Anxiety/enzymology , Benzamides/pharmacology , Carbamates/pharmacology , Central Nervous System Agents/pharmacology , Enzyme Inhibitors/pharmacology , Fever/enzymology , Hypothalamus/enzymology , Inflammation/drug therapy , Inflammation/enzymology , Macrophages/drug effects , Macrophages/enzymology , Microglia/drug effects , Microglia/enzymology , Nociceptive Pain/enzymology , Random Allocation , Rats , Rats, Sprague-Dawley
2.
Eur J Pharm Sci ; 111: 38-45, 2018 Jan 01.
Article in English | MEDLINE | ID: mdl-28943444

ABSTRACT

The current study investigated the effect of organoselenium compound p,p'-methoxyl-diphenyl diselenide [(OMePhSe)2], free or incorporated into nanocapsules, on behavioral, biochemical and molecular alterations in an inflammatory pain model induced by complete Freund's adjuvant (CFA). Male Swiss mice received an intraplantar injection of CFA in the hindpaw and 24 h later they were treated via the intragastric route with a single (OMePhSe)2 administration, in its free form (dissolved in canola oil) or (OMePhSe)2 NC. The anti-hypernociceptive time- and dose-response curves were carried out using the von Frey hair test. Biochemical and histological parameters were determined in samples of injected paws and those of cerebral contralateral cortex were collected to determine immuno content of inflammatory proteins. Both (OMePhSe)2 forms reduced the hypernociception induced by CFA as well as attenuated the altered parameters of the inflammatory process in the paw (paw edema, myeloperoxidase and histological). However, the (OMePhSe)2 NC had a more prolonged anti-hypernociceptive action (7h) at a lower dose (10mg/kg) and superior effects on the paw alterations than the free compound form (4h and 25mg/kg). Furthermore, independent of the (OMePhSe)2 form, its administration decreased the MAPKs pathway activation (JNK;ERK1,2; p38) as well as iNOS, COX-2, Nf-κB and IL-1ß protein contents in the cerebral contralateral cortex that were increased by paw CFA injection. Therefore, (OMePhSe)2 NC had superior anti-inflammatory action, which possibly occurs by the inflammatory protein content modulation and also attenuates paw biochemical and histological inflammatory alterations induced by CFA injection.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Behavior, Animal/drug effects , Drug Carriers/chemistry , Nanocapsules/chemistry , Nociceptive Pain/drug therapy , Organoselenium Compounds/therapeutic use , Animals , Anti-Inflammatory Agents/administration & dosage , Disease Models, Animal , Dose-Response Relationship, Drug , Inflammation , Male , Mice , Nociceptive Pain/enzymology , Nociceptive Pain/immunology , Organoselenium Compounds/administration & dosage , Pain Measurement , Peroxidase/metabolism , Time Factors
3.
Life Sci ; 128: 15-23, 2015 May 01.
Article in English | MEDLINE | ID: mdl-25744405

ABSTRACT

AIMS: Postoperative pain is a major problem. Electroacupuncture (EA) has been accepted as a useful and low-risk complementary therapy for post-operative pain. Animal studies indicate that surgical incision activates p38 MAPK in the spinal microglia, which critically contributes to post-incisional nociceptive development. How EA affects incision-induced p38 activation is important but yet to be fully elucidated. METHODS: Male adult rats received plantar incision (PI) at the right hind paw followed by 30-min EA of 4-Hz, one of two intensities (3 and 10mA), and at right ST36 (Zusanli) acupoint immediately after PI and for 3 successive days. EA analgesia was evaluated by von Frey fibers and Hargreaves' tests. Spinal p38 activation was examined by immunostaining. In separate groups, SB203580, a p38 inhibitor, was intrathecally injected alone or with EA to test the combining effect on nociception and spinal phospho-p38. KEY FINDINGS: EA of 10-mA significantly ameliorated mechanical allodynia, but 3-mA did not. None of them altered thermal hyperalgesia. Repeated EA could not inhibit phospho-p38 in the PI rats, contrarily, EA per se significantly induced phospho-p38 in the normal rats. Intrathecal SB203580 injection dose-dependently prevented PI-induced allodynia. Combination of low-dose SB203580 and 3-mA EA, which were ineffective individually, profoundly reduce post-PI allodynia. SIGNIFICANCE: We demonstrated that 10-mA EA exerts a significant inhibition against post-PI mechanical hypersensitivity via a p38-independent pathway. Importantly, co-treatment with low-dose p38 inhibitor and 3-mA EA can counteract spinal phospho-p38 to exert strong analgesic effect. Our finding suggests a novel strategy to improve EA analgesic quality.


Subject(s)
Electroacupuncture , Nociceptive Pain/prevention & control , Pain, Postoperative/prevention & control , p38 Mitogen-Activated Protein Kinases/metabolism , Acupuncture Analgesia , Animals , Hindlimb/pathology , Hyperalgesia/enzymology , Hyperalgesia/prevention & control , Imidazoles/administration & dosage , Injections, Spinal , Male , Microglia/enzymology , Nociceptive Pain/enzymology , Pain, Postoperative/enzymology , Phosphorylation , Protein Processing, Post-Translational , Pyridines/administration & dosage , Rats, Sprague-Dawley , Spinal Cord/enzymology , Spinal Cord/pathology , p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors
SELECTION OF CITATIONS
SEARCH DETAIL